ConductScience.org, home

Paper37484262

Mechanistic insight into the bioactivity of prodigiosin-entrapped lipid nanoparticles against triple-negative breast, lung and colon cancer cell lines.

Gugu TH and 9 others. Heliyon, 2023. Cited by 3 papers, by iCite. Retracted.

Cite this record

ConductScience Library. Mechanistic insight into the bioactivity of prodigiosin-entrapped lipid nanoparticles against triple-negative breast, lung and colon cancer cell lines. Papers, record 37484262. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37484262

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Mechanistic insight into the bioactivity of prodigiosin-entrapped lipid nanoparticles against triple-negative breast, lung and colon cancer cell lines.
PubMed
Journal
Heliyon
PubMed
Year
2023
PubMed
Publication types
Journal Article, Retracted Publication
PubMed
Citations, by iCite
3
iCite
Relative citation ratio, by iCite
0.54
iCite
Retracted
Yes, by PubMed's record
PubMed
Revised in PubMed
2024-04-15
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gugu THThaddeus H
2Eze COChristopher O
3Kenechukwu FCFranklin C
4Khumaini Mudhar Bintang MAMuhammd A
5Patil SBSanjay B
6Basarkar GDGanesh D
7Attama AAAnthony A
8Ibezim ECEmmanuel C
9Upasani CDChandrashekhar D
10Srichana TTeerapol

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Retracted by38618648Retraction notice to "Mechanistic insight into the bioactivity of prodigiosin-entrapped lipid nanoparticles against triple-negative breast, lung and colon cancer cell lines" [Heliyon 9 (2023) e16963].https://conductscience.org/library/papers/38618648

Source PubMed

Download CSV of comments and corrections

References43

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130400387Biological Potential and Mechanism of Prodigiosin from Serratia marcescens Subsp. lawsoniana in Human Choriocarcinoma and Prostate Cancer Cell Lines.Int J Mol Sci2018https://conductscience.org/library/papers/30400387PubMed
222929442Drug transport across the blood-brain barrier.J Cereb Blood Flow Metab2012https://conductscience.org/library/papers/22929442PubMed
324583638Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation.Cell Death Differ2014https://conductscience.org/library/papers/24583638PubMed
436577970Rise of the natural red pigment 'prodigiosin' as an immunomodulator in cancer.Cancer Cell Int2022https://conductscience.org/library/papers/36577970PubMed
527573798Spiro[pyrrolidine-3, 3´-oxindole] as potent anti-breast cancer compounds: Their design, synthesis, biological evaluation and cellular target identification.Sci Rep2016https://conductscience.org/library/papers/27573798PubMed
630065243Systems analysis of intracellular pH vulnerabilities for cancer therapy.Nat Commun2018https://conductscience.org/library/papers/30065243PubMed
711828428Synthesis and biological evaluation of nonylprodigiosin and macrocyclic prodigiosin analogues.Chembiochem2001https://conductscience.org/library/papers/11828428PubMed
817406391Sulforhodamine B colorimetric assay for cytotoxicity screening.Nat Protoc2006https://conductscience.org/library/papers/17406391PubMed
911015311Prodigiosin from the supernatant of Serratia marcescens induces apoptosis in haematopoietic cancer cell lines.Br J Pharmacol2000https://conductscience.org/library/papers/11015311PubMed
1024247721Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53.Cancer Res2014https://conductscience.org/library/papers/24247721PubMed
1130042582Antioxidant and antimicrobial activity of bioactive prodigiosin produces from Serratia marcescens using agricultural waste as a substrate.J Food Sci Technol2018https://conductscience.org/library/papers/30042582PubMed
1235163625Disruption of Kidney-Immune System Crosstalk in Sepsis with Acute Kidney Injury: Lessons Learned from Animal Models and Their Application to Human Health.Int J Mol Sci2022https://conductscience.org/library/papers/35163625PubMed
1326652344Swelling of poly(N-isopropylacrylamide) P(NIPA)-based hydrogels with bacterial-synthesized prodigiosin for localized cancer drug delivery.Mater Sci Eng C Mater Biol Appl2016https://conductscience.org/library/papers/26652344PubMed
1426344956Prodigiosin and its potential applications.J Food Sci Technol2015https://conductscience.org/library/papers/26344956PubMed
1516126233Non-apoptotic concentrations of prodigiosin (H+/Cl- symporter) inhibit the acidification of lysosomes and induce cell cycle blockage in colon cancer cells.Life Sci2005https://conductscience.org/library/papers/16126233PubMed
1634967848
Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019.
JAMA Oncol2022https://conductscience.org/library/papers/34967848PubMed
179705273Prodigiosins as a new group of H+/Cl- symporters that uncouple proton translocators.J Biol Chem1998https://conductscience.org/library/papers/9705273PubMed
1811036689The natural functions of secondary metabolites.Adv Biochem Eng Biotechnol2000https://conductscience.org/library/papers/11036689PubMed
1927799526Prodigiosin inhibits Wnt/β-catenin signaling and exerts anticancer activity in breast cancer cells.Proc Natl Acad Sci U S A2016https://conductscience.org/library/papers/27799526PubMed
2017671126Triple-negative breast cancer: clinical features and patterns of recurrence.Clin Cancer Res2007https://conductscience.org/library/papers/17671126PubMed

See all 43 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
38794306Lipid Nanoparticles in Lung Cancer Therapy.Pharmaceutics2024https://conductscience.org/library/papers/38794306PubMed
38275722The Golgi Apparatus as an Anticancer Therapeutic Target.Biology (Basel)2023https://conductscience.org/library/papers/38275722PubMed

Download CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ATR545PubTator's text mininghttps://conductscience.org/library/genes/545NCBI Gene
CTNNB11499PubTator's text mininghttps://conductscience.org/library/genes/1499NCBI Gene
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
PNP4860PubTator's text mininghttps://conductscience.org/library/genes/4860NCBI Gene
SFTPC6440PubTator's text mininghttps://conductscience.org/library/genes/6440NCBI Gene
TP537157PubTator's text mininghttps://conductscience.org/library/genes/7157NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37484262

GET https://conductscience.org/api/papers/v1/37484262/references?page=2